US Needed Simple Pragmatic COVID-19 Trial For Repurposing Candidates, Woodcock Says

 
• By Derrick Gingery

One such trial is being developed, but was needed early in the pandemic to answer many lingering questions about potential COVID-19 treatments.

Janet Woodcock, John Farley, Sally Seymour of FDA speak with AMA President Susan Bailey.
(Clockwise from bottom right) Acting Commissioner Janet Woodcock, Office of Infectious Disease Director John Farley and Division of Pulmonology, Allergy, Critical Care Director Sally Seymour, and AMA President Susan Bailey discussed COVID-19 therapeutics during an AMA webinar. • Source: Screenshot

More from Clinical Trials

More from R&D